Lupin receives FDA OK for generic Banzel
Generic Banzel is a prescription add-on medication approved for the treatment of seizures associated with Lennox-Gastaut syndrome in pediatric patients 1 year of age and older and in adults.
The Food and Drug Administration has given Lupin the green light for rufinamide tablets, 100 mg, 200 mg and 400 mg, which is the generic of Eisai’s Banzel.
Generic Banzel is a prescription add-on medication approved for the treatment of seizures associated with Lennox-Gastaut syndrome in pediatric patients 1 year of age and older and in adults.
[Read more: Lupin receives FDA OK for generic Edarbi]
The product will be manufactured at Lupin’s facility in Goa, India.
Rufinamide tablets has a market value of roughly $164 million, according to June 2022 IQVIA data.
[Read more: FDA approves 3 Lupin generics]